Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Recurrent Plasma Cell Myeloma
- Interventions
- Drug: DexamethasoneDrug: Ixazomib CitrateOther: Laboratory Biomarker AnalysisBiological: Pembrolizumab
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT03506360
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Conditions
- Multiple MyelomaMyeloma
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 75
- Registration Number
- NCT03500445
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 5
- Registration Number
- NCT03492138
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia in RemissionB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideBiological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateBiological: OfatumumabDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03488225
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 56
- Registration Number
- NCT03481556
- Locations
- 🇨🇿
Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava, Czechia
🇫🇷Hôpital Morvan, Brest, France
Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery
- Conditions
- Paravertebral Block
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 1
- Registration Number
- NCT03480308
- Locations
- 🇪🇬
Amonios Khalil gerges, Assiut, Egypt
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
- Conditions
- Nausea Post ChemotherapyNauseaEmesisVomitingChemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 130
- Registration Number
- NCT03478605
- Locations
- 🇷🇺
N.N. Blokhin Cancer Research Center, Moscow, Russian Federation
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Refractory B Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 7
- Registration Number
- NCT03472573
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
- Conditions
- Acute Lymphocytic Leukemia, PediatricB-cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: Chimeric Antigen Receptor T-Cell TherapyDrug: FludarabineDrug: CyclophosphamideDrug: TocilizumabDrug: CytarabineDrug: EtoposideDrug: Dexamethasone
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2023-02-24
- Target Recruit Count
- 18
- Registration Number
- NCT03467256
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Myeloid LeukemiaAMLNHLMyelodysplastic SyndromeMultiple MyelomaMDSNon-Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT03465540
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.